Tarsus Pharmaceuticals, Inc. Common Stock (TARS)

Price$58.93

Value ScoreD

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-38.77%

Price vs S&P 500 (4W)-11.61%

VGM Score52.70

Market Capitalization$2.56B

All Metrics

Book Value / Share (Quarterly)$8.11

P/TBV (Annual)10.34x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)159.53%

Cash Flow / Share (Quarterly)$-0.73

Price vs S&P 500 (YTD)-38.39%

Gross Margin (TTM)93.48%

Net Profit Margin (TTM)-9.02%

EPS (TTM)$-1.13

10-Day Avg Trading Volume0.70M

EPS Excl Extra (TTM)$-1.13

EPS (Annual)$-1.59

ROI (Annual)-15.97%

Gross Margin (Annual)93.20%

Net Profit Margin (5Y Avg)-224.30%

Cash / Share (Quarterly)$9.04

Revenue Growth QoQ (YoY)106.87%

ROA (Last FY)-11.81%

Revenue Growth TTM (YoY)128.99%

EBITD / Share (TTM)$-1.17

ROE (5Y Avg)-36.06%

Operating Margin (TTM)-9.50%

Cash Flow / Share (Annual)$-0.52

P/B Ratio7.32x

P/B Ratio (Quarterly)8.56x

Net Income / Employee (Annual)$-179,500

EV / Revenue (TTM)4.72x

Net Interest Coverage (TTM)-7.94x

ROA (TTM)-8.89%

EPS Incl Extra (Annual)$-1.59

Current Ratio (Annual)3.85x

Quick Ratio (Quarterly)3.53x

3-Month Avg Trading Volume0.61M

52-Week Price Return36.74%

Revenue / Employee (TTM)$1,446,200

Tangible BV / Share (Quarterly)$7.95

P/S Ratio (Annual)5.66x

Asset Turnover (Annual)0.80x

52-Week High$85.25

Operating Margin (5Y Avg)-233.48%

EPS Excl Extra (Annual)$-1.59

CapEx CAGR (5Y)84.59%

26-Week Price Return-22.84%

Quick Ratio (Annual)3.72x

13-Week Price Return-21.71%

Total Debt / Equity (Annual)0.21x

Current Ratio (Quarterly)3.74x

Enterprise Value$2.53B

Asset Turnover (TTM)0.98x

Book Value / Share Growth (5Y)-0.07%

Revenue / Employee (Annual)$1,219,900

Pretax Margin (Annual)-14.26%

Cash / Share (Annual)$9.81

3-Month Return Std Dev41.94%

Gross Margin (5Y Avg)93.94%

Net Income / Employee (TTM)$-130,400

ROE (Last FY)-19.34%

Net Interest Coverage (Annual)-26.58x

EPS Basic Excl Extra (Annual)$-1.59

P/FCF (TTM)87.17x

Receivables Turnover (TTM)6.57x

Total Debt / Equity (Quarterly)0.21x

EPS Incl Extra (TTM)$-1.13

Receivables Turnover (Annual)14.05x

ROI (TTM)-11.70%

P/S Ratio (TTM)4.78x

Pretax Margin (5Y Avg)-224.19%

Revenue / Share (Annual)$10.80

Tangible BV / Share (Annual)$7.90

Forward P/E74.46x

Price vs S&P 500 (52W)8.53%

Year-to-Date Return-27.45%

5-Day Price Return-4.59%

EPS Normalized (Annual)$-1.59

ROA (5Y Avg)-25.72%

Net Profit Margin (Annual)-14.72%

Month-to-Date Return-6.62%

Cash Flow / Share (TTM)$-3.86

EBITD / Share (Annual)$-1.68

Operating Margin (Annual)-15.72%

LT Debt / Equity (Annual)0.21x

ROI (5Y Avg)-30.49%

LT Debt / Equity (Quarterly)0.21x

EPS Basic Excl Extra (TTM)$-1.13

P/TBV (Quarterly)8.73x

P/B Ratio (Annual)10.12x

Inventory Turnover (TTM)9.58x

Pretax Margin (TTM)-8.20%

Book Value / Share (Annual)$8.07

Price vs S&P 500 (13W)-31.45%

Beta0.51x

P/FCF (Annual)808.74x

Revenue / Share (TTM)$12.46

ROE (TTM)-14.19%

52-Week Low$38.51

vGradeD

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.16est. -0.38

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.31

4.40

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	D	$58.93
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company developing first-in-class therapeutics for eye care. Its lead product, XDEMVY, is an investigational eye drop for treating Demodex blepharitis, with additional candidates in development for ocular rosacea and other ophthalmic conditions.